Form 4 Filing: Kiselak Tomas Acquires (Grant) shares of $SYRE

STOCK AWARD / GRANT

⚡ MATERIALITY: 1/10

corporate issuer

Spyre Therapeutics, Inc.

Ticker: $SYRE

Transaction Value

Counted once, on the joint filing

Price/Share: same trade as the other owners on this filing

transaction date

2026-05-27

Shares: 8,026

Market Price Activity

HillSignal AI Analytical Report

SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Kiselak Tomas, holds the title of Director at Spyre Therapeutics, Inc..

On 2026-05-27, the insider transacted 8,026 shares.This filing names several owners for the same trade; its value is counted once, on the first owner's entry.

Executive Summary Summary

Kiselak Tomas (Director) was granted $0 of $SYRE

Post-Transaction Position: 8,026 shares

SEC Accession No: 0001636282-26-000069 (CIK: 1830177)

Verified Multi-Source Index

Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.

SEC EDGAR FilingView Source Form 4

Yahoo Finance$SYRE Quote & Profile

OpenCorporates RegistryVerify Corporate Identity

Google News$SYRE News Coverage